Renovaro Biosciences Inc. (RENB)

NASDAQ: RENB · IEX Real-Time Price · USD

1.350

-0.050 (-3.57%)

At close: Jul 19, 2024, 12:00 AM

1.340

-0.010 (-0.74%)

Pre-market: Jul 22, 2024, 8:38 AM EDT

Renovaro Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Year Ending	TTM	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020	Jun 30, 2019	2018 - 2017
Net Income	-53.93	-39.68	-113.43	-26.72	-11.42	-18.02	Upgrade
Depreciation & Amortization	0.12	0.11	0.12	0.12	0.37	0.07	Upgrade
Share-Based Compensation	4.46	3.54	5.49	1.44	1.03	2.16	Upgrade
Other Operating Activities	38.53	24.26	92.09	4.54	-0.44	7.27	Upgrade
Operating Cash Flow	-10.82	-11.77	-15.73	-20.61	-10.46	-8.51	Upgrade
Capital Expenditures	-0.05	-0.03	-0.01	-0.05	-0.18	-0.72	Upgrade
Acquisitions	0.07	0	0	0	0	0	Upgrade
Change in Investments	-1.23	0	0	0	0	0	Upgrade
Investing Cash Flow	-1.21	-0.03	-0.01	-0.05	-0.18	-0.72	Upgrade
Share Issuance / Repurchase	4.87	5.64	4.81	33.15	1	6.02	Upgrade
Debt Issued / Paid	4.43	-1.12	-0.56	-0.55	6.2	0	Upgrade
Financing Cash Flow	9.3	4.52	4.25	32.6	7.2	6.02	Upgrade
Exchange Rate Effect	0.1	-0.01	-0.01	0.03	-0.14	0	Upgrade
Net Cash Flow	-2.64	-7.3	-11.49	11.97	-3.59	-3.32	Upgrade
Free Cash Flow	-10.87	-11.8	-15.74	-20.66	-10.64	-9.22	Upgrade
Free Cash Flow Per Share	-0.10	-0.21	-0.30	-0.44	-0.23	-0.25	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).